Treatment of Postherpetic Neuralgia with Gastroretentive Gabapentin: Interaction of Patient Demographics, Disease Characteristics, and Efficacy Outcomes

To understand how patient demographics and patient-reported disease characteristics relate to successful management of postherpetic neuralgia (PHN), integrated data from Phase 3 and Phase 4 studies of patients with PHN (n=546) who received once-daily gastroretentive gabapentin (G-GR, 1800 mg) were analyzed. There were widespread, networked, positive correlations among efficacy endpoints—pain qualities on the Visual Analog Scale (VAS) and Brief Pain Inventory (BPI), measures of pain interference on the BPI, and Patient Global Impression of Change (PGIC)—most likely characterized by positive feedback loops, in which pain interferes with patient functioning, and poor functioning enhances pain.

from The Journal of Pain http://ift.tt/1NNunD7
via IFTTT